Egg allergy remains one of the most prevalent food allergies in early childhood, posing significant challenges to affected families and healthcare systems due to its potential severity and the need for lifelong dietary restrictions. Australia, in particular, has experienced some of the world’s highest rates of food allergy, with estimates revealing that nearly one in every ten infants is allergic to one or more foods. The alarming prevalence motivated researchers led by Associate Professor Jennifer Koplin and Associate Professor Rachel Peters to evaluate the real-world impact of revised dietary recommendations implemented to curb this trend.

The paradigm shift from previous infant feeding recommendations is striking. During the 1990s and early 2000s, prevailing guidance often encouraged delaying the introduction of allergenic foods such as eggs until after the first year of life, especially if there was a familial predisposition to allergies. This cautious delay was thought to reduce sensitization risk. However, mounting evidence heralded a reversal: earlier exposure to allergenic foods might promote immune tolerance rather than sensitization. Consequently, the 2016 Australian guidelines recommended introducing well-cooked egg and other allergenic foods, including smooth peanut butter, shortly after solid foods are introduced, typically around six months of age.

The investigative team employed rigorous experimental methodologies, assessing allergic outcomes longitudinally and applying consistent diagnostic criteria for egg allergy across the cohorts. The data underscored a remarkable population-level impact, substantiating the hypothesis that early allergen introduction can positively modulate the immune system’s response and reduce allergy sensitization. Of particular interest was the amplified benefit observed among infants with eczema, a condition widely recognized as a major risk factor for food allergies. In this subgroup, the incidence of egg allergy plummeted dramatically—from 35 percent down to 22 percent—highlighting a potentially critical window for intervention among high-risk populations.

Mechanistically, these findings align with immunological theories of oral tolerance, where early, controlled exposure to dietary antigens during critical periods of immune system development educates the immune response to accept rather than mount pathogenic attacks against common food proteins. This form of immunomodulation crucially depends on the timing, dose, and form of the allergen presented to the infant’s gastrointestinal tract, with well-cooked egg protein appearing optimal for such tolerance induction given its reduced allergenicity compared to raw forms.

Despite these promising developments, the study authors emphasize that egg allergy remains a common clinical problem, underscoring the necessity for ongoing research to unravel additional factors influencing allergy development. Genetic predisposition, environmental exposures, microbiome composition, and other immunoregulatory pathways are active areas of inquiry that may yield adjunct prevention strategies or therapeutic targets. Indeed, the observation that some infants still develop egg allergy despite adherence to the new guidelines points to the multifactorial etiology of food allergies, demanding a holistic and nuanced approach to prevention.

The research carries profound implications not only for clinical allergy practice but also for public health policy. By demonstrating that evidence-based changes in infant feeding guidelines can materially reduce food allergy prevalence, this work provides a roadmap for other nations grappling with rising allergy rates. Moreover, it serves as an impetus for healthcare providers to actively counsel parents on the timing and manner of allergenic food introduction, dispelling outdated notions that delayed exposure is protective.

The study further advises incorporation of other common allergenic foods such as cow’s milk, fish, sesame, wheat, and tree nuts before the child’s first birthday, consistent with a broader strategy aimed at fostering immune tolerance through dietary diversity in infancy. This integrative approach may cumulatively attenuate the allergy burden and improve long-term health outcomes.

Publication of these findings in the esteemed journal JAMA Pediatrics adds further weight to the evidence base, attracting attention from clinicians, researchers, and policymakers globally. The rigorous peer-reviewed validation of results enhances confidence in recommending these changes widely across pediatric and nutritional guidelines.

Looking forward, the researchers advocate for continued surveillance and longitudinal studies to monitor the sustained effects of early allergen introduction on allergy prevalence, severity, and quality of life. Additionally, exploration of underlying immunological mechanisms through translational research will deepen understanding and inform next-generation interventions.

Parents and caregivers are encouraged to follow current guidelines and introduce well-cooked egg and other recommended allergenic foods soon after the initiation of solids, typically around six months of age, as this study provides reassurance that such practices are both safe and beneficial in allergy prevention.

In summary, this pivotal research marks a turning point in combating childhood egg allergy, demonstrating that evidence-driven changes to infant feeding guidelines can drive meaningful public health improvements. The findings articulate a clear message: early dietary exposure to common allergenic foods represents a viable strategy for reducing allergy risk and enhancing lifelong health trajectories.

Subject of Research: People
Article Title: Egg Allergy Prevalence Before and After Guidelines for Earlier Egg Introduction
News Publication Date: 8 June 2026
Web References: DOI: 10.1001/jamapediatrics.2026.2080
References: Research published in JAMA Pediatrics
Keywords: Allergies, Food Allergy, Egg Allergy, Infant Feeding Guidelines, Immune Tolerance, Pediatric Allergy Prevention, Early Allergen Introduction, Eczema, Public Health Policy

Recent research spearheaded by the Murdoch Children’s Research Institute (MCRI) in collaboration with the University of Melbourne has revealed compelling evidence that feminizing gender-affirming hormone therapy induces profound remodeling of plasma proteins, shifting the molecular landscape within the body to better mirror a person’s gender identity. This work not only deepens our mechanistic understanding of hormone-driven biological plasticity but also opens novel pathways for personalized medical management in transgender healthcare.

The study meticulously analyzed over 5,000 distinct blood proteins from 40 adult transgender women undergoing feminizing hormone therapy, enrolling participants through the Austin Hospital. By comparing plasma protein profiles prior to treatment and after six months, researchers detected significant protein expression changes that realigned these biomarkers towards those typically observed in cisgender women. This pioneering approach leveraged extensive proteomic technologies to capture a comprehensive biological signature of hormone-induced shifts at a molecular level.

Remarkably, among the proteins significantly altered were key biomarkers linked to reproductive function and endocrine regulation. The researchers noted a pronounced decrease in proteins traditionally associated with male reproductive physiology and fertility. Concurrently, they observed elevated expression of proteins integral to lipid metabolism, breast tissue development, immune system modulation, and cardiovascular health. These dual-directional changes underscore the potent systemic influence of sex hormones beyond mere phenotypic characteristics.

Associate Professor Boris Novakovic of MCRI emphasized that the findings illustrate the plasticity of human biology well into adulthood. “Our results demonstrate that gender-affirming hormone therapy remodels critical plasma proteins responsible for sexually dimorphic traits,” he explained. “This dynamic modulation of blood biomarkers reflects the clinical effects observed and may consequentially adjust disease susceptibility profiles in transgender women, including autoimmune and cardiovascular disorders.”

Intriguingly, the protein alterations noted in trans women undergoing hormone therapy paralleled those documented in cisgender women receiving hormone replacement therapy for menopausal symptoms. This parallelism not only validates the biological relevance of the observed proteomic shifts but also reinforces the concept that exogenous hormones can recalibrate internal molecular milieus along sex-specific lines, offering broader insights into hormone biology.

Utilizing a vast reference dataset from a UK biobank comprising over 55,000 individuals, the study robustly benchmarked the proteomic changes against normative sex-specific protein expressions. This comparative analysis affirmed that feminizing hormone treatment can effectively realign the plasma proteome of transgender women, erasing many typical male-female protein expression disparities. These insights pave the way for revisiting clinical guidelines around biomarker interpretations and diagnostic criteria specific to transgender populations.

The investigators highlight the clinical implications inherent in these biological remodelings. Given the altered immune-related biomarkers, the modulation of risk for allergic and autoimmune diseases—which generally exhibit higher prevalence in females—may increase. Conversely, a potentially reduced risk of cardiovascular disease, historically more common in males, emerges as a notable consequence. Such nuanced shifts in disease susceptibility underscore the necessity for sophisticated, gender-sensitive healthcare models tailored to the unique physiological trajectories of trans individuals.

Professor Ada Cheung, head of the Trans Health Research Group at the University of Melbourne, accentuates the translational potential of these findings. She envisions a future wherein continuous proteomic monitoring could revolutionize the personalization of hormone therapy regimens. “By tracking protein biomarkers dynamically, clinicians might better calibrate hormone dosages, preemptively identify cardiovascular or immunological side effects, and enhance overall treatment efficacy,” Cheung noted. “This proteomic perspective heralds a transformative era in transgender medicine, blending molecular diagnostics with individualized care.”

The researchers contend that existing healthcare protocols for transgender patients warrant significant revision. Beyond acknowledging gender identity, medical management must incorporate detailed molecular phenotyping to anticipate and mitigate long-term health risks associated with hormone therapy. Emerging proteomic technologies could become indispensable tools for longitudinal health surveillance, facilitating early interventions before the onset of adverse outcomes.

The study’s rigorous longitudinal design and high-throughput proteomic analysis mark an impressive advancement in sex hormone research. Prior models often relied on hormonal levels alone, but this protein-centric approach captures downstream physiological effects with unprecedented resolution. Such comprehensive molecular profiling sets a new standard for studying endocrine therapies not only in transgender care but also in broader contexts involving hormone modulation.

This inquiry propels the field towards a refined understanding of sex hormone interaction with human biology. The evidence asserts that even beyond developmental windows, systemic hormone fluctuations can pivotally alter foundational biological signatures. These insights challenge static views of sex differences and emphasize a continuum of hormonal influence with profound health implications, underscoring the need for flexible clinical paradigms that integrate gender diversity.

Published in the prestigious journal Nature Medicine, this study stands as a landmark contribution to both endocrinology and transgender health research. Its revelations about the malleability of the plasma proteome in response to feminizing hormone therapy offer hope for optimized treatments that honor the complexity of human identity while enhancing quality of life and health outcomes for transgender individuals worldwide.

Subject of Research: People

Article Title: Remodelling of the plasma proteome by sex hormones in a longitudinal clinical trial of feminizing gender-affirming hormone therapy

News Publication Date: 20-Oct-2025

Web References:
DOI: 10.1038/s41591-025-04023-9

References:
Nhi NL Nguyen, Den Celestra, Lachlan M. Angus, Toby Mansell, Rebecca Shepherd, Bo Won Kim, Bridget Arman, Georgiana Cabau, Tania O. Crișan, Leo A. B. Joosten, Camille Laberthonnière, David Burgner, Gilda Tachedjian, Musa Mhlanga, Rachel A. Davey, Ken C. Pang, Ada S. Cheung, Richard Saffery, Boris Novakovic. “Remodelling of the plasma proteome by sex hormones in a longitudinal clinical trial of feminizing gender-affirming hormone therapy.” Nature Medicine, 2025.

Traditionally, newborn screening programs rely on biochemical analyses conducted on blood samples collected via heel prick within days of birth. These tests, while vital, are limited to detecting a small panel of mostly metabolic disorders—currently 32 conditions in Australia. However, genomic sequencing offers a radically broader surveillance, examining the entire genome for variations in hundreds of genes associated with early-onset, treatable diseases. This means potentially hundreds of additional conditions, encompassing rare immunodeficiencies, childhood cancers, cardiac anomalies, and neurological disorders, could be identified within the critical neonatal period.

The BabyScreen+ study enrolled 1,000 newborns in Victoria, applying whole-genome sequencing to detect pathogenic variants in 605 genes linked to severe, treatable diseases manifesting early in life. Employing the same blood spot sample collected during the routine heel prick, researchers demonstrated that sequencing could be completed within 14 days, aligning with the timeliness expectations necessary for neonatal care. This pilot confirmed the feasibility of integrating genomic approaches into existing public health frameworks without imposing additional invasive procedures on families.

Beyond operational feasibility, the study explored parental attitudes toward genomic newborn screening. Results were overwhelmingly supportive; 99.5% of participant parents endorsed universal availability of the testing, and 93% expressed willingness to recommend it to others. This counters concerns regarding potential apprehension about complex genetic information and reinforces the perceived value of early genomic insights in fostering proactive healthcare decisions.

Clinically, the study uncovered 16 infants harboring genetic variants indicating an increased risk for serious conditions; strikingly, only one of these diagnoses would have been detected through standard newborn screening methods. One particularly dramatic case involved a diagnosis of hemophagocytic lymphohistiocytosis (HLH), a rare immunodeficiency disorder characterized by uncontrolled immune activation causing organ damage. Early genomic detection enabled life-saving interventions, including a successful bone marrow transplant, highlighting the profound impact of genomic information in altering disease trajectories.

These findings bear heavily on the future of personalized medicine in pediatrics. Genomic medicine’s expanding capabilities challenge existing public health infrastructures, which have largely been static in the scope and scale of conditions screened at birth. As Professor Zornitza Stark, a clinical geneticist and co-leader of the study, emphasizes, the integration of genomic sequencing into newborn screening has the potential to redefine early disease detection and treatment, saving lives and mitigating lifelong disability.

Yet, the groundbreaking promise of widespread genomic newborn screening is accompanied by multifaceted ethical, logistical, and societal considerations. The generation of comprehensive genomic data raises significant issues concerning data storage security, privacy, equitable access across diverse populations, and the complexities surrounding informed consent, particularly as the child matures into adulthood. The dynamic nature of genomic interpretation and the implications for insurance and personal autonomy underscore the need for robust policy frameworks and ongoing public dialogue.

Associate Professor Sebastian Lunke, Head of the VCGS Division of Genetics and Genomics, underscores the importance of strategic stewardship to ensure that genomic data benefits families responsibly. This involves designing systems that maintain parental and, eventually, individual agency over genomic information, alongside transparent communication about the scope and limitations of testing. Expanding research into community preferences and outcomes is vital to inform evidence-based health policies that support scalable and ethical implementation.

The poignant family narrative of Giselle, diagnosed through the BabyScreen+ study, brings these scientific advances vividly into focus. Despite appearing healthy, Giselle’s early diagnosis of HLH enabled her medical team to initiate timely treatment, including a lifesaving bone marrow transplant with her mother serving as a partially matched donor. Her story underscores the life-altering potential of prompt genomic diagnosis, which circumvented delayed recognition and allowed a trajectory towards recovery and a hopeful future.

This pilot study’s compelling clinical outcomes and parental endorsement suggest that genomic newborn screening is not merely a technological curiosity but a practicable evolution in neonatal healthcare. The capacity to detect a comprehensive array of genetic conditions early can transform preventive medicine, reduce healthcare burdens, and enhance quality of life from infancy through adulthood.

As Australia and the global medical community contemplate scaling genomic screening, the integration of cutting-edge sequencing technologies into public health must be balanced with ethical diligence, cost-effectiveness, and equitable frameworks. The BabyScreen+ study sets a precedent, demonstrating that genomic medicine can be responsibly harnessed on a population level to save lives and provide families with invaluable knowledge about their children’s health trajectories.

Ultimately, the future of newborn screening is poised to shift from a limited biochemical assay to a comprehensive genomic evaluation—offering a blueprint for precision public health and personalized pediatric care that could redefine the standards of early disease detection worldwide.

Subject of Research: People

Article Title: Genomic newborn screening: feasibility, acceptability and clinical outcomes

Web References:
BabyScreen+ study – MCRI
Nature Medicine
DOI: 10.1038/s41591-025-03986-z

Keywords: Genetics, Genomics, Genome sequencing

The research focuses on the lipidomic profile of infants who have been breastfed for at least six months, linking their lower incidence of infections and diminished markers of chronic inflammation to the presence of rare, bioactive lipid molecules. Breastfeeding’s broad immunological benefits have long been recognized, but this study dives much deeper into the molecular constituents of breastmilk, particularly a class of lipids known as plasmalogens. These molecules, which are essentially absent in infant formula, appear to play a pivotal role in modulating the neonatal immune environment, mitigating inflammatory cascades that can predispose infants to a variety of chronic conditions later in life.

Lipids, a diverse group of essential nutrients, form the structural and functional foundation of cellular membranes and act as signaling molecules in immune responses. Using plasma samples from nearly 900 infants enrolled in the Barwon Infant Study—a large-scale longitudinal birth cohort study in Australia—the researchers performed an exhaustive analysis of approximately 800 individual lipids and related metabolic markers. This comprehensive profiling identified significant alterations in the plasma lipidome of breastfed infants compared to their non-breastfed peers, pointing to systemic metabolic changes induced by breastfeeding.

Among the lipids scrutinized, plasmalogens emerged as uniquely abundant in the plasma of breastfed infants. Plasmalogens are ether phospholipids known for their antioxidant properties and ability to maintain membrane integrity under oxidative stress. Their role in immune regulation is increasingly recognized, as they can dampen pro-inflammatory signaling pathways and maintain redox balance within immune cells. The study posits that the high concentration of plasmalogens in breastmilk may be a critical factor in curbing systemic inflammation in infants, which is crucial during this vulnerable developmental period when their immune system is still maturing.

Dr. Toby Mansell of MCRI emphasized that the presence of plasmalogens exclusively in breastmilk highlights a significant nutritional gap in infant formulas, which could potentially be addressed by incorporating these lipids synthetically or through novel supplementation strategies. Understanding the precise mechanisms by which plasmalogens exert their anti-inflammatory effects could pave the way for innovative therapies aimed at infants who cannot be breastfed, thereby equipping them with similar immunological defenses as their breastfed counterparts.

The implications of these findings extend far beyond preventing acute infections. Chronic low-grade inflammation during infancy has been implicated in the etiology of a range of pediatric conditions such as allergies, asthma, and metabolic disorders like diabetes. By elucidating how breastfeeding mediates systemic metabolic and immunological shifts, the study provides a compelling biological rationale for global public health initiatives advocating exclusive breastfeeding for at least the first six months of life.

Contributing to the study, Dr. Satvika Burugupalli from the Baker Institute highlighted the multifaceted nature of breastmilk, which is not simply nourishment but a complex bioactive fluid containing antibodies, immune cells, and a tailored lipid profile that collectively condition the infant’s immune system. This intricate biological synergy appears instrumental in establishing a balanced immune milieu, reducing the risk of aberrant inflammatory responses that could culminate in chronic disease.

Moreover, the research collaborated with institutions such as the University of Melbourne, Deakin University, Barwon Health, Northwestern University, and the Florey Institute of Neuroscience and Mental Health, reflecting a robust interdisciplinary approach integrating immunology, metabolomics, and pediatric epidemiology. This confluence of expertise enhances the credibility and translational potential of the findings, underscoring the importance of collaborative science in addressing complex health issues.

The data also align with emerging insights from Generation Victoria (GenV), a large prospective cohort study led by MCRI, which collects extensive biological specimens, including thousands of breast milk and infant stool samples. This resource allows for unprecedented longitudinal tracking of nutritional, microbiome, and immune parameters, thereby complementing and extending the initial observations made in the Barwon Infant Study. The amalgamation of these data sets promises to deepen our understanding of how early-life nutrition shapes lifelong health trajectories.

By deploying advanced metabolomic platforms and applying rigorous mediation analysis, the research team was able to dissect the pathways linking breastfeeding, lipid metabolic alterations, and reductions in inflammation. This analytical framework transcends simple observational correlations, offering mechanistic insights that could inform both nutritional guidance and the development of targeted interventions to mitigate early inflammatory risks.

As global health organizations emphasize the critical importance of breastfeeding, this study provides concrete molecular evidence supporting such recommendations. It also raises urgent questions about how infant formula can be reformulated to mimic the immunoprotective properties of breastmilk more closely. Future research inspired by these findings may unravel additional bioactive compounds in breastmilk and decipher their roles, enabling the design of next-generation infant nutrition that approximates the natural gold standard.

In conclusion, the intricate interplay between breastmilk-derived lipids and infant inflammation revealed by this study marks a significant scientific advance. It underscores breastfeeding not only as an optimal nutritional strategy but as a sophisticated immunomodulatory process crucial for infant development and long-term health. This work opens exciting new avenues for translational research aimed at bridging immunological disparities in infancy and reducing the burden of chronic childhood and adult diseases through improved early-life nutrition.

Subject of Research: People

Article Title: The protective effect of breastfeeding on infant inflammation: a mediation analysis of the plasma lipidome and metabolome

Web References:

• Murdoch Children’s Research Institute: https://www.mcri.edu.au/
• Baker Heart and Diabetes Institute: https://www.baker.edu.au/
• Barwon Infant Study: https://www.barwonhealth.org.au/service/barwon-infant-study/
• BMC Medicine: https://bmcmedicine.biomedcentral.com/
• DOI: https://doi.org/10.1186/s12916-025-04343-0
• GenV (Generation Victoria): https://www.genv.org.au/

References:
Burugupalli S., Mansell T., Wang T., George A.D., Paul S., Saffery R., Tang M.L.K., McDade T.W., Beyene H.B., Duong T., Vuillermin P., Ponsonby A.-L., Barwon Infant Study Investigator Group, Burgner D.P., Meikle P.J. The protective effect of breastfeeding on infant inflammation: a mediation analysis of the plasma lipidome and metabolome. BMC Medicine. DOI: 10.1186/s12916-025-04343-0

Keywords: Breastfeeding, Immune disorders, Infectious diseases

The study assessed 83 children aged between five and 18 years who were admitted to The Royal Children’s Hospital (RCH) for complicated appendectomies, specifically focusing on those with severe cases where traditional post-operative care usually entails extended hospital stays. Out of those studied, 35 children were assessed as suitable candidates for the Hospital in the Home (HITH) program. This innovative program allows specialized care to be provided in a home setting, significantly deviating from the conventional method that emphasizes continuous hospital supervision.

An essential aspect of the research was the need for intravenous antibiotics as part of the post-surgical care plan. All participants required a minimum of five days of antibiotic treatment following their procedures. Under the HITH model, trained nurses administered these medications with daily visits to the children’s homes, allowing for careful monitoring and immediate response to any potential complications. The study’s results indicated that those children who received at-home care not only recovered more quickly but also experienced fewer complications, suggesting that home recovery could be both an effective and safe alternative to traditional hospital care.

The lead researcher, Associate Professor Penelope Bryant from MCRI, emphasized that the findings challenge the longstanding belief that children undergoing serious surgeries must remain hospitalized for their recovery. The data indicated a substantial reduction—up to 35 percent—in the duration of hospital stays without compromising patient safety or extending antibiotic treatment durations unnecessarily. This presents a significant paradigm shift in pediatric post-operative care and opens the door to further exploration of home-based recovery models.

The implications of this study are profound, particularly in light of the increasing demand for hospital resources. Every year, more than 300 patients are admitted to RCH with appendicitis, with a considerable portion suffering from severe complications like ruptured appendices. Implementing the HITH program could alleviate the strain on hospital capacity, allowing medical facilities to focus on patients with more critical needs while freeing up much-needed bed space.

Associate Professor Warwick Teague, a co-researcher, highlighted that the HITH approach is particularly timely, especially given the insights gained during the COVID-19 pandemic, which saw a surge in remote care models. The pandemic forced many healthcare systems to innovate and adapt quickly; as a result, many healthcare facilities began to recognize the value of at-home care options. This study provides further evidence that effective post-operative care can transition from the hospital to the home, adequately balancing safety and patient health outcomes.

Moreover, this trend has far-reaching economic implications. According to the study, the HITH program could save hospitals over $1,400 a day and families $300 daily, addressing financial burdens exacerbated by rising healthcare costs. Enhancing recovery protocols through such innovative strategies is pivotal for improving quality of life for patients and their families while simultaneously contributing to the sustainability of healthcare resources.

Furthermore, the findings of this study could redefine surgical practices and protocols as medical professionals consider the growing body of evidence supporting home recovery models. Traditionally, follow-up care after surgeries for severe appendicitis has necessitated hospital visits for assessments by surgical teams. However, this research suggests that trained non-surgical clinicians can effectively manage these patients’ care at home, provided they work collaboratively with surgical teams to ensure comprehensive monitoring and intervention when necessary.

As this research paves the way for a shift towards more patient-centered care, it also raises essential questions surrounding the selection criteria for children suitable for such models. Identifying the specific characteristics and health conditions that qualify patients for home recovery will be key to scaling this approach and integrating it into standard practice. Clinicians must be equipped to assess and determine when home-based care will be beneficial, ensuring patient safety while maximizing the benefits of this innovative model.

This study not only highlights the successes of the HITH approach in managing recovery for complicated appendicitis but also stimulates broader discussions about the future of pediatric surgical care. As healthcare continues to evolve, the lessons learned from this research could have implications well beyond appendicitis, influencing practices related to other surgical conditions and across different age groups.

In conclusion, the research by MCRI illustrates a groundbreaking shift in pediatric surgical recovery practices, suggesting that with the proper support and infrastructure, children can recover from complex surgeries effectively in a home environment. The implications of these findings resonate far beyond the immediate patient population and challenge the traditional paradigms of hospital recovery, promoting a future where at-home care could become a standard practice. As healthcare continues to adapt to new challenges and opportunities, further research will be necessary to optimize these models and ensure that they meet the evolving needs of patients, families, and the healthcare system.

Subject of Research: Children recovering from complicated appendicitis using Hospital-in-the-Home model
Article Title: Getting children home sooner on intravenous antibiotics with a Hospital-in-the-Home model of care for complicated appendicitis
News Publication Date: [Not provided]
Web References: [Not provided]
References: [Not provided]
Image Credits: [Not provided]

Keywords: Pediatric surgery, Hospital-at-home, Complicated appendicitis, Post-operative care, Healthcare innovation.